Published in Blood on December 05, 2007
Targeting the ubiquitin system in cancer therapy. Nature (2009) 3.27
Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov (2010) 2.90
Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77
Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol (2012) 2.26
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther (2009) 1.88
Proteasome inhibitors in the treatment of multiple myeloma. Leukemia (2009) 1.68
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer (2014) 1.52
Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem Biol (2009) 1.47
Unfolded protein response in cancer: the physician's perspective. J Hematol Oncol (2011) 1.45
Proteasome inhibitors in cancer therapy. J Cell Commun Signal (2011) 1.38
The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta (2011) 1.36
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol (2013) 1.30
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit. Biochem J (2010) 1.18
Advances in and applications of proteasome inhibitors. Curr Opin Chem Biol (2008) 1.17
Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) (2011) 1.13
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol (2011) 1.13
DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica (2012) 1.06
Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem (2012) 1.05
Therapeutic targeting of cancer cell cycle using proteasome inhibitors. Cell Div (2012) 0.98
Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors. Cancer Cell (2014) 0.94
Nature of pharmacophore influences active site specificity of proteasome inhibitors. J Biol Chem (2010) 0.94
Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. J Med Chem (2013) 0.92
Inhibitors of the immunoproteasome: current status and future directions. Curr Pharm Des (2013) 0.92
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med (2014) 0.92
Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS One (2013) 0.91
Novel therapeutics in multiple myeloma. Hematology (2012) 0.89
The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. J Biol Chem (2013) 0.89
Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Curr Oncol Rep (2008) 0.88
The 26S proteasome is a multifaceted target for anti-cancer therapies. Oncotarget (2015) 0.88
Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics (2010) 0.84
Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. Onco Targets Ther (2012) 0.82
Boron chemicals in diagnosis and therapeutics. Future Med Chem (2013) 0.82
Targeting ubiquitination for cancer therapies. Future Med Chem (2015) 0.82
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. Biologics (2013) 0.81
Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones. Org Biomol Chem (2011) 0.81
Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget (2016) 0.80
Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors. Bioorg Med Chem (2010) 0.80
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. Biomed Res Int (2015) 0.80
The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery. Am J Blood Res (2011) 0.79
Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding. PLoS One (2013) 0.79
Selective growth inhibition of human malignant melanoma cells by syringic acid-derived proteasome inhibitors. Cancer Cell Int (2013) 0.78
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica (2015) 0.77
Emodin potentiates the antiproliferative effect of interferon α/β by activation of JAK/STAT pathway signaling through inhibition of the 26S proteasome. Oncotarget (2016) 0.77
Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors. J Med Chem (2013) 0.77
Experimental approaches in the treatment of multiple myeloma. Ther Adv Hematol (2011) 0.76
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? Onco Targets Ther (2016) 0.76
The future of proteasome inhibitors in relapsed/refractory multiple myeloma. Oncology (Williston Park) (2011) 0.75
The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone (2016) 0.75
Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors. Cancer Sci (2014) 0.75
Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol (2014) 0.75
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
The genome of the model beetle and pest Tribolium castaneum. Nature (2008) 6.50
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med (2005) 6.45
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer (2008) 5.07
Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol (2009) 5.01
Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood (2007) 4.73
A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59
Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell (2006) 4.48
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med (2007) 3.83
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res (2011) 3.50
Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant (2011) 3.49
Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem Biol (2002) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol (2012) 3.18
Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One (2010) 3.14
Isolation of renal progenitor cells from adult human kidney. Am J Pathol (2005) 3.12
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med (2015) 3.05
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77
Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell (2005) 2.76
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 2.76
Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J Biol Chem (2004) 2.75
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood (2007) 2.67
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol (2013) 2.63
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure (2006) 2.56
Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int (2012) 2.47
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells (2007) 2.39
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood (2011) 2.37
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene (2002) 2.36
Isolation and characterization of a stem cell population from adult human liver. Stem Cells (2006) 2.25
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol (2010) 2.24
A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A (2002) 2.24
Human liver stem cells improve liver injury in a model of fulminant liver failure. Hepatology (2013) 2.24
Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One (2012) 2.23
Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J (2004) 2.23
Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes (2003) 2.17
Soil Respiration in European Grasslands in Relation to Climate and Assimilate Supply. Ecosystems (2008) 2.17
Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med (2004) 2.16
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood (2005) 2.15
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood (2013) 2.14
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc Natl Acad Sci U S A (2004) 2.09
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood (2009) 2.08
Perioperative dexamethasone administration and risk of bleeding following tonsillectomy in children: a randomized controlled trial. JAMA (2012) 2.08
Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity (2013) 2.05
OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell (2013) 2.05
Purine and pyrimidine (P2) receptors as drug targets. J Med Chem (2002) 2.05
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood (2007) 2.03
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol (2015) 2.03
Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell (2007) 2.01
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol (2013) 1.99
Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res (2010) 1.96
Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol (2011) 1.95
Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev (2012) 1.91
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant (2012) 1.88
Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J (2008) 1.88
Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood (2011) 1.88
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood (2002) 1.87
Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol Cell Biol (2004) 1.86
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma (2008) 1.85
Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg (2009) 1.84
Chemical synthesis of ubiquitin, ubiquitin-based probes, and diubiquitin. Angew Chem Int Ed Engl (2010) 1.83
Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods (2005) 1.78
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood (2011) 1.76
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood (2011) 1.76
Comparative genomic analysis of the Tribolium immune system. Genome Biol (2007) 1.74